Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Aurinia deal with Teva keeps Lupkynis generic in check until '36

21 August 2026 · By · Wire by Fusion42

Published

21 August 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at fiercepharma.com →

◆ Verified

Fusion42 · 21 August 2026 · Fusion42 review

Aurinia Pharmaceuticals has settled a patent infringement dispute with Teva Pharmaceuticals, delaying the entry of Teva's generic version of Lupkynis in the US until December 2036, extending market exclusivity.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 21 Aug 2026 and 22 Aug 2026.

◆ ◆ The Wire takeaway

Patent battle outcomes now block generic entry for over a decade, locking in Aurinia's control of Lupkynis in the US. If you work in pharma IP or drug launch timing, realign your plans to this extended exclusivity window.

◆ Coverage

2 sources · first reported 21 Aug 2026 · latest 22 Aug 2026

◆ Related on Wire

◆ Topics

Biotechpatent-infringementgeneric-delaypharma-settlementmarket-exclusivityauriniateva